The University of Chicago Header Logo

Connection

Thomas F. Gajewski to Enzyme Inhibitors

This is a "connection" page, showing publications Thomas F. Gajewski has written about Enzyme Inhibitors.
Connection Strength

0.647
  1. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246.
    View in: PubMed
    Score: 0.341
  2. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007 Sep 15; 110(6):1982-8.
    View in: PubMed
    Score: 0.233
  3. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr Opin Investig Drugs. 2004 Dec; 5(12):1279-83.
    View in: PubMed
    Score: 0.049
  4. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.